Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $266.48 and traded as low as ...

J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...

Johnson & Johnson (J&J) raised its 2024 profit and sales forecasts on October 15, thanks to strong sales of oncology drugs, ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

The firm reported growth slightly ahead of our expectations.

The company also revised its operational earnings forecast from $10.05 to $9.91. The V-Wave acquisition is expected to dilute ...

Johnson & Johnson raised its 2024 profit and sales forecasts following strong oncology drug sales, notably Darzalex. Despite ...